Latest Healthcare It News

Epsilon Healthcare’s subsidiary, Epsilon Pharma, has signed a three-year manufacturing agreement with New Zealand’s Puro to supply medicinal cannabis products to the UK and Europe, marking a significant step in its international expansion.

BCAL Diagnostics has launched its Avantect blood tests for pancreatic and ovarian cancer with encouraging early uptake and is advancing its BREASTESTplus breast cancer test towards broader clinical use.

Jcurve Solutions has reported a robust first half of FY26, posting a 32% increase in revenue and a remarkable 478% jump in EBITDA, while upgrading its full-year revenue guidance amid ongoing customer churn challenges.

Amcor has reported robust second quarter and half-year results for fiscal 2026, driven by the Berry acquisition and operational synergies. The company reaffirmed its full-year guidance and declared a higher quarterly dividend.

Vitrafy Life Sciences has delivered key milestones in the first half of FY26, including a strategic partnership with IMV Technologies and progress in clinical studies, while maintaining a strong cash position to support its U.S. expansion and product launches.

Ryman Healthcare has unveiled a refreshed strategy focused on growing recurring earnings and optimising its portfolio, targeting a $150 million sustainable cash flow improvement and $500 million cash release by FY29. The company plans to resume dividends from FY28, underpinned by a resilient balance sheet and disciplined capital management.

Memphasys has lodged regulatory submissions for its Felix™ System in Australia and India, following CE Mark approval, while progressing UK market entry under the CE Mark transition framework.

Rhythm Biosciences has secured a multi-year commercial manufacturing agreement with US-based Quansys Biosciences to produce ColoSTAT® reagent kits, paving the way for broader market rollout of its colorectal cancer diagnostic test.

Arena REIT has announced its December 2025 quarter distribution of 4.8125 cents per stapled security, reflecting steady income from its social infrastructure portfolio. The distribution includes components relevant for tax purposes, underscoring the REIT’s ongoing compliance and investor transparency.

Neurotech International has secured ethics approval to launch its Beyond Harmony Phase 3 clinical trial of NTI164 for autism spectrum disorder, marking a key step toward regulatory submissions in Australia and the US.

Emyria Limited reports that approximately 67% of patients treated for PTSD remain in remission over 12 months post-treatment, highlighting the potential for lasting recovery and cost-effective care.

CurveBeam AI has received the first A$4 million tranche of a planned A$10 million strategic investment from a leading Chinese orthopaedic device company, marking a significant step in its expansion into the Chinese market.